Key Highlights
- Upstream Bio (NASDAQ:UPB) rose 13.06% on October 16, at an indicated pre-market price of USD 3.81, at an indicated price of USD 3.81, at an indicated price of USD 3.81, at an indicated price of USD 3.81.
- Biofrontera (NASDAQ:BFRI) rose 9.79% on October 16, at an indicated pre-market price of USD 0.9300, at an indicated price of USD 0.9300, at an indicated price of USD 0.9300, at an indicated price of USD 0.9300.
- Aldeyra Therapeutics (NASDAQ:ALDX) rose 7.83% on October 16, at an indicated pre-market price of USD 0.7950, at an indicated price of USD 0.7950, at an indicated price of USD 0.7950, at an indicated price of USD 0.7950.
- KALA BIO (NASDAQ:KALA) rose 7.39% on October 16, at an indicated pre-market price of USD 0.2064, at an indicated price of USD 0.2064, at an indicated price of USD 0.2064, at an indicated price of USD 0.2064.
Upstream Bio (NASDAQ:UPB): Pre-Market Move
Upstream Bio (NASDAQ:UPB) was indicated up 13.06% at USD 3.81 in pre-market trading on October 16. Upstream Bio, a clinical-stage biotechnology company developing a TSLP receptor antibody, was indicated up 13.06% at USD 3.81 pre-market on October 16, implying a prior close near USD 3.3699, with no company-specific disclosure dated October 15 or 16 identified in filings or newswire coverage. Index-level pre-market trading on October 16 was calm, with S&P 500 and Nasdaq-100 exchange-traded funds up about 0.25% and 0.19% ahead of bank and insurer earnings from Travelers, Truist and M&T Bank, while micro-cap names with thin pre-market liquidity moved sharply on little information. A USD 0.01 change on a USD 3.81 price equals about 0.3%, so tick size and thin pre-market liquidity magnify percentage moves in low-priced shares. The move therefore appears to reflect sector sentiment and trading flows rather than a reported event, and it may reverse at the open. The indicated price of USD 3.81 compares with an implied prior close of about USD 3.3699, a move of about USD 0.4401 a share. The indicated price of USD 3.8100 compares with an implied prior close near USD 3.3699, a move of about USD 0.4401 a share. A one-cent move on a USD 3.81 stock equals about 0.3%, so tick size magnifies percentage changes. The price is above the USD 1.00 Nasdaq minimum bid threshold, though liquidity remains thin in pre-market trading. Thin pre-market liquidity, tiny market values and financing or listing pressures can reverse indicated moves quickly at the open. By size of pre-market move it ranks 1 of 5 in this group. What to watch next: company filings, financing and regular-session volume.
Biofrontera (NASDAQ:BFRI): Pre-Market Move
Biofrontera (NASDAQ:BFRI) was indicated up 9.79% at USD 0.9300 in pre-market trading on October 16. Biofrontera, a dermatology pharmaceutical company, was indicated up 9.79% at USD 0.9300 pre-market on October 16, implying a prior close near USD 0.8471, with no company-specific disclosure dated October 15 or 16 identified in filings or newswire coverage. A USD 0.01 change on a USD 0.9300 price equals about 1.1%, so tick size and thin pre-market liquidity magnify percentage moves in low-priced shares. The indicated price of USD 0.9300 compares with an implied prior close of about USD 0.8471, a move of about USD 0.0829 a share. The indicated price of USD 0.9300 compares with an implied prior close near USD 0.8471, a move of about USD 0.0829 a share. A one-cent move on a USD 0.93 stock equals about 1.1%, so tick size magnifies percentage changes. The price is below USD 1.00, the Nasdaq minimum bid threshold, which exposes the company to compliance notices, reverse splits and dilution. By size of pre-market move it ranks 2 of 5 in this group.
Aldeyra Therapeutics (NASDAQ:ALDX): Pre-Market Move
Aldeyra Therapeutics (NASDAQ:ALDX) was indicated up 7.83% at USD 0.7950 in pre-market trading on October 16. Aldeyra Therapeutics was indicated up 7.83% at USD 0.7950 pre-market after closing at USD 0.7904 on October 14 and slipping about 5% on October 15, and the stock is down about 85% over twelve months. The FDA issued a third complete response letter for reproxalap in dry eye disease on March 16, 2026, and on September 29 the company announced its intent to submit a formal dispute resolution request, with the submission and a meeting expected in the fourth quarter. The company says its cash funds operations into 2029, and its market value of about USD 45 million sits close to cash, which means the market assigns little value to the pipeline. The shares trade below USD 1.00, which exposes them to Nasdaq minimum-bid-price rules, and analysts' targets of about USD 6.60 contrast with the USD 2 target and Neutral rating from H.C. Wainwright. The indicated price of USD 0.7950 compares with an implied prior close of about USD 0.7373, a move of about USD 0.0577 a share. The indicated price of USD 0.7950 compares with an implied prior close near USD 0.7373, a move of about USD 0.0577 a share. A one-cent move on a USD 0.80 stock equals about 1.3%, so tick size magnifies percentage changes. By size of pre-market move it ranks 3 of 5 in this group. What to watch next: the FDA appeal outcome, cash runway and listing compliance.
KALA BIO (NASDAQ:KALA): Pre-Market Move
KALA BIO (NASDAQ:KALA) was indicated up 7.39% at USD 0.2064 in pre-market trading on October 16. KALA BIO, an ophthalmology biotechnology company, was indicated up 7.39% at USD 0.2064 pre-market on October 16, implying a prior close near USD 0.1922, with no company-specific disclosure dated October 15 or 16 identified in filings or newswire coverage. A USD 0.01 change on a USD 0.2064 price equals about 4.8%, so tick size and thin pre-market liquidity magnify percentage moves in low-priced shares. The indicated price of USD 0.2064 compares with an implied prior close of about USD 0.1922, a move of about USD 0.0142 a share. The indicated price of USD 0.2064 compares with an implied prior close near USD 0.1922, a move of about USD 0.0142 a share. A one-cent move on a USD 0.21 stock equals about 4.8%, so tick size magnifies percentage changes. By size of pre-market move it ranks 4 of 5 in this group.
Inovio Pharmaceuticals (NASDAQ:INO): Pre-Market Move
Inovio Pharmaceuticals (NASDAQ:INO) was indicated up 5.77% at USD 1.10 in pre-market trading on October 16. Inovio, a DNA medicines company, was indicated up 5.77% at USD 1.10 pre-market on October 16, implying a prior close near USD 1.0400, with no company-specific disclosure dated October 15 or 16 identified in filings or newswire coverage. A USD 0.01 change on a USD 1.10 price equals about 0.9%, so tick size and thin pre-market liquidity magnify percentage moves in low-priced shares. The indicated price of USD 1.10 compares with an implied prior close of about USD 1.0400, a move of about USD 0.0600 a share. The indicated price of USD 1.1000 compares with an implied prior close near USD 1.0400, a move of about USD 0.0600 a share. A one-cent move on a USD 1.10 stock equals about 0.9%, so tick size magnifies percentage changes. By size of pre-market move it ranks 5 of 5 in this group.
Where Things Stand
The group of 5 pre-market movers shows how thin liquidity and tiny market values produce large percentage swings, so each name needs its own catalyst check. Upstream Bio (NASDAQ:UPB) rose 13.06%. Biofrontera (NASDAQ:BFRI) rose 9.79%. Aldeyra Therapeutics (NASDAQ:ALDX) rose 7.83%. KALA BIO (NASDAQ:KALA) rose 7.39%. Inovio Pharmaceuticals (NASDAQ:INO) rose 5.77%. Moves on stocks this small often reverse, so the balance of evidence favors waiting for filings and the next session. Direction remains unknown, and each name carries its own risks. Check each company's filings for the drivers behind the move, verify the latest filings before acting, and treat the figures as a snapshot.






Please wait processing your request...